Improving the safety and efficacy of anticoagulation therapy

| Submission date | Recruitment status | Prospectively registered |
|-------------------|--------------------------|-------------------------------|
| 21/10/2010 | No longer recruiting | ☐ Protocol |
| Registration date | Overall study status | Statistical analysis plan |
| 21/10/2010 | Completed | Results |
| Last Edited | Condition category | Individual participant data |
| 30/09/2016 | Haematological Disorders | ☐ Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Hilary Wynne

Contact details

Newcastle upon Tyne Hospitals NHS Foundation Trust Queen Victoria Road Newcastle Upon Tyne United Kingdom NE1 4LP

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 8579

Study information

Scientific Title

Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through vitamin K: a single centre randomised controlled trial

Study objectives

To investigate whether daily supplementation with vitamin K improves the stability of anticoagulation control in patients on chronic therapy with warfarin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Sunderland Research Ethics Committee, 08/06/2009, ref: 09/H0904/25

Study design

Single-centre non-randomised observational screening cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Not specified

Study type(s)

Screening

Participant information sheet

Not available in web format, please contact Maggie Fearby on +44 (0)191 282 1632 to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Blood; Subtopic: Blood (all Subtopics); Disease: Non-malignant haematology

Interventions

Randomised (blinded) to vitamin K/placebo 150 µg orally once daily for 6 months. Follow-up at 1, 2, 4, 8, 12, 16, 20, and 24 weeks post initial dose.

Intervention Type

Supplement

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Vitamin K

Primary outcome measure

Percent time within target INR (calculated by the method of interpolation) for the study period, measured at baseline and weeks 1, 2, 4, 8, 12, 16, 20 and 24 weeks.

Secondary outcome measures

- 1. Clinical events of major (defined as bleeding that led to loss of 2 units of blood over a 7 day period
- 2. Days attending anticoagulation clinic to monitor and achieve target International Normalised Ratio (INR)
- 3. Markers of lack of efficacy including recurrent thrombosis
- 4. The number of warfarin dose changes
- 5. Quality of life questionnaires recorded at baseline and repeated at the end of the study

Overall study start date

01/07/2010

Completion date

01/01/2013

Eligibility

Key inclusion criteria

- 1. Long term warfarin therapy
- 2. Aged greater than or equal to 18 years
- 3. Male and female

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned sample size: 180

Key exclusion criteria

- 1. Abnormal hepatic or renal function
- 2. Impairment of cognitive function

Date of first enrolment

01/07/2010

Date of final enrolment

01/01/2013

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle Upon Tyne
United Kingdom
NE1 4LP

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

Sponsor details

Queen Victoria Road Newcastle Upon Tyne England United Kingdom NE1 4LP

Sponsor type

Hospital/treatment centre

Website

http://www.newcastle-hospitals.org.uk

ROR

https://ror.org/05p40t847

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) programme

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?HRA research summary28/06/2023NoNo